MX370270B - Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. - Google Patents
Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.Info
- Publication number
- MX370270B MX370270B MX2017011277A MX2017011277A MX370270B MX 370270 B MX370270 B MX 370270B MX 2017011277 A MX2017011277 A MX 2017011277A MX 2017011277 A MX2017011277 A MX 2017011277A MX 370270 B MX370270 B MX 370270B
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- treatment
- glucosylceramide synthase
- synthase inhibitors
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
En la presente descripción se describen compuestos de la Fórmula 1, métodos para producir tales compuestos, composiciones farmacéuticas y medicamentos que contienen tales compuestos y métodos para usar tales compuestos para tratar o prevenir enfermedades o condiciones asociadas con la enzima glucosilceramida sintasa (GCS).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562131703P | 2015-03-11 | 2015-03-11 | |
PCT/US2016/021706 WO2016145153A1 (en) | 2015-03-11 | 2016-03-10 | Glucosylceramide synthase inhibitors for the treatment of diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017011277A MX2017011277A (es) | 2018-02-19 |
MX370270B true MX370270B (es) | 2019-12-09 |
Family
ID=55629120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017011277A MX370270B (es) | 2015-03-11 | 2016-03-10 | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. |
Country Status (10)
Country | Link |
---|---|
US (2) | US10227312B2 (es) |
EP (1) | EP3268355B1 (es) |
JP (1) | JP6649394B2 (es) |
CN (1) | CN107635980A (es) |
AU (1) | AU2016229101B2 (es) |
CA (1) | CA2978458C (es) |
IL (1) | IL254266B (es) |
MX (1) | MX370270B (es) |
NZ (1) | NZ735118A (es) |
WO (1) | WO2016145153A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX370270B (es) * | 2015-03-11 | 2019-12-09 | Biomarin Pharm Inc | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. |
WO2019104011A1 (en) * | 2017-11-21 | 2019-05-31 | Biomarin Pharmaceutical Inc. | Ceramide galactosyltransferase inhibitors for the treatment of disease |
CN111630033A (zh) | 2018-01-23 | 2020-09-04 | 巴斯夫欧洲公司 | 任选取代的二氢异喹啉的制备 |
CN109709202A (zh) * | 2018-12-29 | 2019-05-03 | 辉源生物科技(上海)有限公司 | 一种半乳糖神经酰胺转移酶抑制剂药物的快速筛选方法 |
JP7539382B2 (ja) | 2019-07-29 | 2024-08-23 | 武田薬品工業株式会社 | 複素環化合物 |
WO2021221953A1 (en) * | 2020-04-28 | 2021-11-04 | The Regents Of The University Of Michigan | Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same |
GB202006399D0 (en) * | 2020-04-30 | 2020-06-17 | Syngenta Crop Protection Ag | Microbiocidal compounds |
GB202006386D0 (en) * | 2020-04-30 | 2020-06-17 | Syngenta Crop Protection Ag | Microbiocidal Compounds |
GB202006480D0 (en) * | 2020-05-01 | 2020-06-17 | Syngenta Crop Protection Ag | Microbiocidal compounds |
CN115433157B (zh) * | 2022-11-09 | 2023-02-07 | 苏州凯瑞医药科技有限公司 | 一种依利格鲁司特中间体的制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002293764A (ja) * | 2001-01-26 | 2002-10-09 | Takeda Chem Ind Ltd | アミノエタノール誘導体 |
GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
JP2008519840A (ja) | 2004-11-10 | 2008-06-12 | ジェンザイム・コーポレイション | 糖尿病の処置方法 |
WO2008011483A2 (en) | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds |
US20100105687A1 (en) | 2007-03-06 | 2010-04-29 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
EP2167485B1 (en) * | 2007-05-31 | 2015-09-30 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
WO2009117150A2 (en) * | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
CA2731685A1 (en) * | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
MX2011003517A (es) | 2008-10-03 | 2011-05-25 | Genzyme Corp | Inhibidores de la glucosilceramida sintasa tipo 2-acilaminopropanol. |
US8961959B2 (en) * | 2011-10-17 | 2015-02-24 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
SI3063141T1 (sl) | 2013-10-29 | 2018-11-30 | Biomarin Pharmaceutical Inc. | N-(1-hidroksi-3-(pirolidinil)propan-2-il)pirolidin-3-karboksamidni derivati kot inhibitorji glukozilceramid sintaze |
MX370270B (es) * | 2015-03-11 | 2019-12-09 | Biomarin Pharm Inc | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. |
-
2016
- 2016-03-10 MX MX2017011277A patent/MX370270B/es active IP Right Grant
- 2016-03-10 CA CA2978458A patent/CA2978458C/en active Active
- 2016-03-10 JP JP2017547460A patent/JP6649394B2/ja active Active
- 2016-03-10 EP EP16711941.1A patent/EP3268355B1/en active Active
- 2016-03-10 AU AU2016229101A patent/AU2016229101B2/en active Active
- 2016-03-10 WO PCT/US2016/021706 patent/WO2016145153A1/en active Application Filing
- 2016-03-10 US US15/556,786 patent/US10227312B2/en active Active
- 2016-03-10 CN CN201680026239.3A patent/CN107635980A/zh active Pending
- 2016-03-10 NZ NZ735118A patent/NZ735118A/en unknown
-
2017
- 2017-09-01 IL IL254266A patent/IL254266B/en active IP Right Grant
-
2019
- 2019-01-18 US US16/252,475 patent/US10759769B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3268355B1 (en) | 2019-06-12 |
US10759769B2 (en) | 2020-09-01 |
NZ735118A (en) | 2022-04-29 |
IL254266B (en) | 2020-06-30 |
MX2017011277A (es) | 2018-02-19 |
CA2978458A1 (en) | 2016-09-15 |
JP2018507887A (ja) | 2018-03-22 |
JP6649394B2 (ja) | 2020-02-19 |
AU2016229101A1 (en) | 2017-09-28 |
CA2978458C (en) | 2024-04-02 |
WO2016145153A1 (en) | 2016-09-15 |
IL254266A0 (en) | 2017-10-31 |
CN107635980A (zh) | 2018-01-26 |
EP3268355A1 (en) | 2018-01-17 |
US10227312B2 (en) | 2019-03-12 |
AU2016229101B2 (en) | 2020-03-05 |
US20190248754A1 (en) | 2019-08-15 |
US20180044302A1 (en) | 2018-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016003486A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
MX370270B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
PH12017501921A1 (en) | Novel compounds | |
MX2017006366A (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa. | |
PH12017500941A1 (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
MY192717A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
SG10201811175WA (en) | Method for treating cancer using a combination of chk1 and atr inhibitors | |
EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
PH12017501095A1 (en) | Piperidine derivatives as hdac1/2 inhibitors | |
MX2016005437A (es) | Derivados de n-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3 -carboxamida como inhibidores de glucosilceramida sintasa. | |
PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
PH12017501735A1 (en) | Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | |
MX2018007517A (es) | Compuestos triciclicos y composiciones como inhibidores de quinasa. | |
MX2017013281A (es) | Metodos para tratar transtornos del almacenamiento lisosomal. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |